This is to inform you that pursuant to Regulation 30 read with Regulation 33 of the Listing Regulations, the Board at its meeting held today i.e., Friday, May 23, 2025, through video Conferencing, ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.1 pts less than Nifty Microcap 250 and 3.0 pts less than its Healthcare Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board of Globalspace Technologies approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025. Standalone FY25 revenue was nearly flat at Rs 2,932.48 lakhs (vs Rs 2,904.80 lakhs in FY24), but net loss narrowed sharply to Rs 183.71 lakhs from Rs 353.11 lakhs, helped by lower exceptional items (Rs 275.65 lakhs vs Rs 385.66 lakhs). Q4 FY25 standalone turned profitable with Rs 8.74 lakhs net profit vs a Rs 403.95 lakhs loss in Q4 FY24. On a consolidated basis, FY25 revenue jumped 48% to Rs 4,304.58 lakhs, driven by subsidiary Innopharm Healthcare (Rs 1,383.92 lakhs revenue), though consolidated net loss still stood at Rs 199.92 lakhs. The Board also re-appointed Maheshwari Maheshwari & Co. as internal auditor for FY26 and granted 75,000 ESOP options to eligible employees. Operating margin compressed from 17% to 12%.
Mixed signals for shareholders: top-line growth at consolidated level and reduced losses are positives, but the company remains loss-making at standalone level, operating margins are under pressure, and the new ESOP grant will cause slight equity dilution.